I wouldn't say the report is amazing, but it's passable. Main takes from both of the divisions probably are:
Life science:
"Our plans are on track to have at least two COVID related and two sepsis-related tests available for use on the EuGeni PLATFORM over the coming 12 months. Whilst sales have already commenced at modest levels, as we clear the various country regulatory processes, further expand our distributor network and grow our test pipeline, we expect revenues to build over the coming 12 months and beyond. In addition, we have our raw material sales. One of our key customers, Ellume, is expanding their manufacturing operations from their Brisbane facility and establishing their US manufacturing base and is pushing their products into the US market."
To those who thinks we've missed the boat, our boat is NOT just Covid-19, we are building a platform, A PLATFORM. Which will host a range of tests, that is the long term vision, as the company is planning to launch 4 new tests in 12 months. Then even for Covid-19, we now know what is required for "additional" regulatory approvals, which in most cases, a mere submission of paperwork that we've already got from CE approval, though in SG and UK, further trials are required. Once those certain approvals are obtained, sales will build even more rapidly.
As it stands, sales have commenced, even though at modest levels, but it will build. I think some people are taking all of this too laterally, too zoned into 1 single test, vs the possibly of an entire platform that is to come. IMO, the potential future revenue streams are enormous, but there are still risks involved, and the ones selling now are not liking the risk, but each to their own.
I think we'll see some rabbits out of hats in September/October.
Energy - on track for commercialisation:
"...we are still expecting the outcome from the evaluation during Q4 2021. If successful, Collaborator 8 has flagged that this event would trigger discussion on commercial agreements for supply. We are also making good technical and commercial progress with another collaborator in Europe and continue to progress plans to launch AnteoX in our own right to the market. The year ahead is shaping up well to deliver a potential breakthrough on the Energy side to go with our Life Science progress."
Interesting how they put "on track for commercialisation" into the Energy section heading to emphasis this. I think things are coming along, but it just takes time - that's just how it is. We've jumped through many hoops with and for Collaborator #8, and so far we've proven AnteoX works, everytime. Jack compares the next 12 months for Energy to the last 12 months of breakthrough/progress we've achieved with life science (EuGeni) - which took us from 1c to 48c and now settling in the teens. Our time will come.
Expand
(20min delay)